Key regions: Australia, Brazil, United Kingdom, Europe, Canada
The Other Vaccines market in G20 has been experiencing notable growth in recent years.
Customer preferences: Consumers are increasingly prioritizing their health and well-being, leading to a rise in demand for preventative healthcare measures such as vaccines. Additionally, the COVID-19 pandemic has heightened awareness of the importance of vaccination, leading to an increased interest in other types of vaccines.
Trends in the market: In the United States, there has been a growing trend towards alternative vaccination schedules, which has led to an increase in demand for individual vaccines rather than combination vaccines. This has resulted in a shift towards more targeted marketing and development of single vaccines. In Europe, there has been a focus on increasing vaccination rates for diseases such as influenza and meningitis, leading to a rise in demand for these vaccines. In Japan, there has been a push towards increasing vaccination rates for HPV, leading to a growth in the HPV vaccine market.
Local special circumstances: In China, the government has implemented a new vaccine procurement policy which has led to an increase in demand for domestically produced vaccines. This has resulted in a shift away from imported vaccines in the Chinese market. In Brazil, there has been a push towards increasing vaccination rates for diseases such as yellow fever and meningitis, leading to a rise in demand for these vaccines.
Underlying macroeconomic factors: The global vaccine market is heavily influenced by government policies and regulations. Changes in government policies, such as the implementation of new procurement policies in China, can have a significant impact on the market. Additionally, the COVID-19 pandemic has led to increased government funding for vaccine development and distribution, which has contributed to the growth of the market. The global aging population and the rise in chronic diseases have also contributed to the growth of the vaccine market, as preventative healthcare measures become increasingly important.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
